PHILADELPHIA, PA / ACCESSWIRE / October 26, 2019 / Kaskela Law LLC announces that it is investigating Surface Oncology, Inc. (Nasdaq:SURF) on behalf of the Company's investors.
In April 2018, Surface Oncology completed its initial public offering ("IPO") of common stock, selling 7.2 million shares of stock to investors at $15.00 per share. Since the time of the IPO, shares of the Company's common stock have declined over 90% in value.
The investigation seeks to determine whether Surface Oncology violated the federal securities laws in connection with and following the Company's IPO of common stock.
Investors who purchased shares of Surface Oncology's common stock and suffered an investment loss are encouraged to contact Kaskela Law LLC at (888) 715-1740, or online at http://kaskelalaw.com/case/surface-oncology-inc/, to receive additional information about this investigation and their legal rights and options.
Kaskela Law LLC exclusively represents investors in securities fraud and shareholder rights litigation in state and federal actions. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.
CONTACT:
D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 258 - 1585
(888) 715 - 1740
www.kaskelalaw.com
[email protected]
SOURCE: Kaskela Law LLC